Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey

被引:29
作者
Boehnke, Kevin F. [1 ]
Gagnier, Joel J. [2 ,3 ]
Matallana, Lynne [4 ,5 ]
Williams, David A. [1 ]
机构
[1] Univ Michigan, Dept Anesthesiol, Sch Med, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA
[2] Univ Michigan, Sch Med, Orthopaed Surg, Ann Arbor, MI USA
[3] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA
[4] Natl Fibromyalgia Assoc, Newport Beach, CA USA
[5] Community Hlth Focus Inc, Ann Arbor, MI USA
关键词
Fibromyalgia; cannabidiol; chronic pain; symptom relief; prevalence; DISORDER; SEIZURES;
D O I
10.1016/j.jpain.2020.12.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cannabidiol (CBD) is widely advertised as helpful for chronic pain management but research is limited. Using a cross-sectional, anonymous survey, we examined patterns of naturalistic CBD use among individuals with fibromyalgia (FM) and other chronic pain conditions. Our objective was to better understand rates of CBD use, reasons for use and discontinuation, communication with healthcare professionals about CBD, and perceptions of CBD effectiveness and safety among people with FM. After excluding incomplete surveys, our study population consisted of N = 2,701 participants with fibromyalgia, primarily in the United States. Overall, 38.1% reported never using CBD, 29.4% reported past CBD use, and 32.4% reported current CBD use. Past-year cannabis use was strongly associated with past or current CBD use. Those using CBD typically did so due to inadequate symptom relief, while those not using CBD typically cited safety concerns as their reason for not using CBD. Two-thirds of participants disclosed CBD use to their physician, although only 33% asked for physician advice on using CBD. Participants used CBD for numerous FM-related symptoms (most commonly pain), and generally reported slight to much improvement across symptom domains. Around half of participants reported side effects, which were typically minor. Our findings are limited by selection bias and our cross-sectional design, which prevents causal associations. In conclusion, CBD use is common among individuals with FM and many individuals using CBD report improvements across numerous FM related symptoms. Our findings highlight the need for additional rigorous studies to better understand CBD's potential for FM management. Perspective: This article indicates that CBD use is common among people with fibromyalgia, and the results suggest that many derive benefit from using CBD across multiple symptoms domains. Clinicians should discuss CBD use with fibromyalgia patients, and future studies are needed to rigorously assess CBD's therapeutic value for fibromyalgia symptoms. (C) 2021 by United States Association for the Study of Pain, Inc.
引用
收藏
页码:556 / 566
页数:11
相关论文
共 57 条
  • [1] Administration USFaD, 2019, WARN LETT TEST RESUL
  • [2] Fibromyalgia
    Bair, Matthew J.
    Krebs, Erin E.
    [J]. ANNALS OF INTERNAL MEDICINE, 2020, 172 (05) : ITC33 - ITC46
  • [3] An internet survey of 2,596 people with fibromyalgia
    Bennett, Robert M.
    Jones, Jessie
    Turk, Dennis C.
    Russell, I. Jon
    Matallana, Lynne
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2007, 8 (1)
  • [4] Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
    Bergamaschi, Mateus M.
    Costa Queiroz, Regina Helena
    Nisihara Chagas, Marcos Hortes
    Gomes de Oliveira, Danielle Chaves
    De Martinis, Bruno Spinosa
    Kapczinski, Flavio
    Quevedo, Joao
    Roesler, Rafael
    Schroeder, Nadja
    Nardi, Antonio E.
    Martin-Santos, Rocio
    Cecilio Hallak, Jaime Eduardo
    Zuardi, Antonio Waldo
    Crippa, Jose Alexandre S.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2011, 36 (06) : 1219 - 1226
  • [5] Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain
    Boehnke, Kevin F.
    Scott, J. Ryan
    Litinas, Evangelos
    Sisley, Suzanne
    Clauw, Daniel J.
    Goesling, Jenna
    Williams, David A.
    [J]. JOURNAL OF PAIN, 2019, 20 (11) : 1362 - 1372
  • [6] Qualifying Conditions Of Medical Cannabis License Holders In The United States
    Boehnke, Kevin F.
    Gangopadhyay, Saurav
    Clauw, Daniel J.
    Haffajee, Rebecca L.
    [J]. HEALTH AFFAIRS, 2019, 38 (02) : 295 - 302
  • [7] Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain
    Boehnke, Kevin F.
    Scott, J. Ryan
    Litinas, Evangelos
    Sisley, Suzanne
    Williams, David A.
    Clauw, Daniel J.
    [J]. JOURNAL OF PAIN, 2019, 20 (07) : 830 - 841
  • [8] Pain Management: Assembling a Tool Kit, Building a Life
    Boehnke, Kevin F.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (21): : 2201 - 2202
  • [9] Labeling Accuracy of Cannabidiol Extracts Sold Online
    Bonn-Miller, Marcel O.
    Loflin, Mallory J. E.
    Thomas, Brian F.
    Marcu, Jahan P.
    Hyke, Travis
    Vandrey, Ryan
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (17): : 1708 - 1709
  • [10] Brenan M., 2019, 14 AM SAY THEY USE C